Shots:

• The P-lll IM-UNITI LTE study involves assessing of Stelara (SC- 90mg- q8w/q12w) vs PBO as maintenance therapy in 1-281 patients with moderate to severe CD. All patients completing 44wks. were eligible to enter the LTE program- continuing their current regimen ~252wks.
• 50%+ patients were randomized to q8w dosing and continued to receive this dosage in the LTE study- maintained CR (57%) and remission (55 %) through 5 yrs. of treatment while (93%) were steroid-free. Among patients who had prior exposure to & failed to TNF-α biologics- clinical remission (59% & 44%) respectively
• Stelara is a fully human mAb & is the first and only biologic treatment to selectively inhibit the (IL)-12 and IL-23 pathways and is approved in the US for multiple diseases
  
   ­ Ref: PRNewswire | Image: Janssen